Company intelligence / Profile preview

Anasens

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

Anasens is commercializing a rapid, quantitative, and connected point-of-care diagnostic platform that uses DNA-based nanosensors to detect a wide range of biomarkers directly from blood or saliva, enabling at-home or on-site testing. The technology is aimed at chronic disease monitoring, illicit drug detection, and therapeutic drug monitoring. The company’s first product, DrugAsens™, is a rapid oral-fluid multidrug test for workplace, law enforcement, and clinical use. Clinical validation of prototypes is underway, but regulatory approvals and additional investment are required before commercialization.

Therapeutic areas: OtherPsychiatry
Modalities: DeviceAptamer
Industry: Protein Biomarker Diagnostics

Partnerships

MAVAND Solutions GmbH (Distribution agreement for DrugAsens™ in select EU countries and Australia, to accelerate commercialization and market access for rapid drug testing)

Beyond the preview

Go deeper on Anasens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anasens.

Explore the full profile